Triple
T5425243
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | relapsing-remitting multiple sclerosis |
E121346
|
entity |
| Predicate | treatedWith |
P2367
|
FINISHED |
| Object |
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
|
E518760
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69bd463b58d88190b258261573de9e91 |
elicitation | completed |
| NER | batch_69bd881598448190a9bb456dee36004b |
ner | completed |
| NED1 | batch_69bf3abbd1e481909ffb443812a9485a |
ned_source_triple | completed |
| NED2 | batch_69bf3c2b9d04819081a946e9f68c4eb2 |
ned_description | completed |
| NEDg | batch_69bf3b663b148190807d35421c911d74 |
nedg | completed |
Created at: March 20, 2026, 2:06 p.m.